Hong Kong stocks movement | CRO Concept stocks rose broadly in the morning as Innovative Drugs continue to expand overseas. The Global interest rate cuts help improve CXO overseas Business.
CRO Concept stocks experienced a general rise in the morning session. As of the time of writing, FRONTAGE (01521) rose by 5.88%, trading at 1.8 HKD; WUXI APPTEC (02359) rose by 4.97%, trading at 57 HKD; WUXI BIO (02269) rose by 3.64%, trading at 18.2 HKD; PHARMARON (03759) rose by 3.21%, trading at 14.14 HKD.
【Brokerage Focus】CITIC SEC指出今年是在底部布局医疗健康产业优秀赛道和头部核心企业的最佳机会.
Golden Owl Finance | CITIC SEC stated that the 43rd J.P. Morgan Healthcare Conference will be held from January 13 to 16, 2025, in San Francisco, USA. As the largest and most content-rich healthcare investment seminar in the industry, it brings together global industry leaders, rapidly growing emerging companies, innovative technology creators, and investment professionals. According to the exchanges disclosed by participating companies, specifically, in the area of Innovative Drugs, the technological iteration and business development around core products/fields remain the growth engines for Pharma; in the CXO and upstream life sciences sector, upstream research and development needs are showing moderate recovery.
【Special Guest V】Deng Shengxing: The mainland has released the detailed rules for the 2025 Autos trade-in policy, benefiting the Autos stocks.
Jinwu Financial News | The Hang Seng Index closed at 19,925 on Monday (20th), up 341 points or 1.7%. The total market turnover for the day was 161.3 billion yuan. The national index rose 126 points or 1.8%, closing at 7,235 points; the Hang Seng TECH Index increased by 116 points or 2.6%, finishing at 4,595 points. The mainland released details on the 2025 automobile trade-in policy, with auto stocks like NIO (09866), BYD (01211), and XPeng (09868) rising by 4% to 4.4%, and Li Auto (02015) increasing by 3%. In the consumer sector, MINISO (09896) rose by 5.7%. US stocks on the week.
Hong Kong stocks are experiencing unusual movements | CRO Concept stocks are leading in gains as the医保丙类目录 is expected to be implemented this year, and Domestic Innovative Drugs are likely to open up payment space.
CRO Concept stocks have risen significantly. As of the time of writing, WUXI APPTEC (02359) rose by 6.36%, trading at 55.2 HKD; GENSCRIPT BIO (01548) increased by 5.64%, trading at 9.93 HKD; WUXI BIO (02269) went up by 5.9%, priced at 19.02 HKD; and PHARMARON (03759) rose by 4.66%, trading at 13.92 HKD.
[Brokerage Focus] CMB International raises WUXI BIO (02269) Target Price by 5.9%, citing positive demand trends as a solid foundation for 2025.
Jinwu Financial News | Zhao Yin International's Research Reports indicate that WUXI BIO (02269) signed a record 151 new projects in 2024, and is entitled to receive $0.14 billion in recent milestone payments. In addition, overseas Operations are progressing steadily, with the Irish biopharmaceutical factory expected to generate profits in 2025. Management reaffirms the 2024 performance guidance, expecting revenue and adjusted Net income (excluding minority interests) to grow by 5-10% year-on-year, and anticipates accelerating revenue growth in 2025. The firm indicates that the company's unique CRDMO business model enables it to better empower client projects in the early research and development phase by directly authorizing projects.
Announcement Selection | Eastern Airlines' passenger turnover increased by nearly 20% last month; Zijin Mining Group and some of its affiliated enterprises were included in the UFLPA entity list.
In 2024, the Metallurgical Corporation of China saw a year-on-year decline in newly signed contracts; last month, Eastern Airlines' passenger turnover increased by nearly 20%.
